Siren,
$4.9B 13F equity value
124 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Siren, covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| SRRK | Scholar Rock Holding Corp | 9,575,013 | $527M | 10.7% |
| KYMR | Kymera Therapeutics Inc | 2,935,830 | $337M | 6.8% |
| ERAS | Erasca Inc | 11,397,781 | $209M | 4.2% |
| MANE | Veradermics Inc | 1,655,374 | $204M | 4.1% |
| TNGX | Tango Therapeutics Inc | 6,179,364 | $193M | 3.9% |
| RVMD | Revolution Medicines Inc | 900,000 | $169M | 3.4% |
| BCAX | Bicara Therapeutics Inc | 5,602,970 | $166M | 3.4% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1,715,476 | $140M | 2.8% |
| ONC | BeOne Medicines AG | 465,000 | $133M | 2.7% |
| EWTX | Edgewise Therapeutics Inc | 3,184,629 | $129M | 2.6% |
Track Siren,'s 13F portfolio: $4.9B in reported holdings, 124 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}